Acanthamoeba Keratitis Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight

The Acanthamoeba Keratitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acanthamoeba Keratitis pipeline products will significantly revolutionize the Acanthamoeba Keratitis market dynamics.

DelveInsight's "Acanthamoeba Keratitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Acanthamoeba Keratitis, historical and forecasted epidemiology as well as the Acanthamoeba Keratitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Acanthamoeba Keratitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Acanthamoeba Keratitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acanthamoeba Keratitis Market Forecast
https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Acanthamoeba Keratitis Market Report:
• The Acanthamoeba Keratitis market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In August 2024, The European Commission granted approval to AKANTIOR for the treatment of Acanthamoeba keratitis.
• In September 2024, SIFI received a Notice of Allowance from the European Patent Office (EPO). Additionally, another patent, already approved in Italy and several EurAsian countries, secures intellectual property rights through 2040.
• In the United States, 95% of patients were contact lens users, with 74% specifically wearing soft contact lenses. Between 2009 and 2015, the number of cases rose, leading to an estimated incidence of one in 21,000 soft contact lens wearers in 2015.
• In the US, the incidence of Acanthamoeba keratitis is estimated at about 1-2 new cases per million contact lens users each year, with roughly 17% of the adult population wearing contact lenses.
• A systematic review estimated that in Italy, the occurrence of eyes affected by Acanthamoeba keratitis was about 2.34 per million people in the general population.
• A prospective survey in the UK reported an overall incidence of 2.35 cases per million, with contact lens users making up 87% of cases. Among them, the incidence of Acanthamoeba keratitis was 26.94 per million.
• Key Acanthamoeba Keratitis Companies: SIFI SpA/Avanzanite Bioscience, and others
• Key Acanthamoeba Keratitis Therapies: AKANTIOR (polihexanide), and others
• The Acanthamoeba Keratitis epidemiology based on gender analyzed that Acanthamoeba Keratitis affect male and female equally

Acanthamoeba Keratitis Overview
Acanthamoeba keratitis is a rare but serious eye infection caused by a microscopic, free-living amoeba called Acanthamoeba. This infection primarily affects the cornea, the transparent outer covering of the eye. Acanthamoeba keratitis is most commonly associated with contact lens wearers but can also occur in non-contact lens users due to exposure to contaminated water or soil.

Get a Free sample for the Acanthamoeba Keratitis Market Report:
https://www.delveinsight.com/report-store/acanthamoeba-keratitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acanthamoeba Keratitis Market
The dynamics of the Acanthamoeba Keratitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
"The current market includes various off-label therapies and surgeries as potential treatment options. Miltefosine (Impavido), an orphan designated drug is used off- label for the treatment of AK. No drug therapy is approved for the indication, and the pipeline is also very narrow. In the pipeline, SIFI is developing a drug named Akantior [Polihexanide (PHMB)], which if approved would be the first drug approved for the treatment of AK that may change the market scenario in the coming year."

Acanthamoeba Keratitis Epidemiology
The epidemiology section offers an in-depth look at the historical, current, and projected epidemiology trends across the seven major countries (7MM) from 2020 to 2034. By examining various studies and expert opinions, it identifies the factors driving present and future trends. This section also includes a comprehensive analysis of the diagnosed patient population and anticipated future patterns.

Acanthamoeba Keratitis Epidemiology Segmentation:
The Acanthamoeba Keratitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Acanthamoeba Keratitis
• Prevalent Cases of Acanthamoeba Keratitis by severity
• Gender-specific Prevalence of Acanthamoeba Keratitis
• Diagnosed Cases of Episodic and Chronic Acanthamoeba Keratitis

Download the report to understand which factors are driving Acanthamoeba Keratitis epidemiology trends @ Acanthamoeba Keratitis Epidemiological Forecast
https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acanthamoeba Keratitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acanthamoeba Keratitis market or expected to get launched during the study period. The analysis covers Acanthamoeba Keratitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acanthamoeba Keratitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Acanthamoeba Keratitis treatment, visit @ Acanthamoeba Keratitis Medications
https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acanthamoeba Keratitis Therapies and Key Companies
• AKANTIOR (polihexanide): SIFI SpA/Avanzanite Bioscience

Scope of the Acanthamoeba Keratitis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Acanthamoeba Keratitis Companies: SIFI SpA/Avanzanite Bioscience, and others
• Key Acanthamoeba Keratitis Therapies: AKANTIOR (polihexanide), and others
• Acanthamoeba Keratitis Therapeutic Assessment: Acanthamoeba Keratitis current marketed and Acanthamoeba Keratitis emerging therapies
• Acanthamoeba Keratitis Market Dynamics: Acanthamoeba Keratitis market drivers and Acanthamoeba Keratitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Acanthamoeba Keratitis Unmet Needs, KOL's views, Analyst's views, Acanthamoeba Keratitis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.